Related Experiment Videos
Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and
Jaqui Walker1, Marco Cattaneo2, Lina Badimon3
1International Aspirin Foundation, 34 Bower Mount Road, Maidstone, Kent ME16 8AU, UK.
Insights
Experts debated optimal antithrombotic strategies for cardiovascular disease (CVD) prevention. Individualized management balancing risks and benefits is key, with future tools aiding treatment decisions for those most likely to benefit.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Cardiovascular disease (CVD) remains a leading cause of mortality globally.
- Antithrombotic therapy plays a crucial role in CVD prevention.
- Optimizing antithrombotic strategies requires balancing efficacy and safety.
Purpose of the Study:
- To discuss and debate optimal antithrombotic strategies for secondary CVD prevention.
- To seek consensus on aspirin dosing and target populations for primary CVD prevention.
- To explore the role of evidence-based medicine in clinical decision-making for CVD prevention.
Main Methods:
- International experts convened at the 2019 International Aspirin Foundation Scientific Conference.
- Discussions and debates focused on current evidence and clinical practice.
- Expert opinion and consensus-building were central to the discussions.
Main Results:
- Complexity in translating evidence into clinical practice was acknowledged.
- Individualized patient management, balancing risks and benefits, was identified as the optimal approach.
- The need for improved decision-making tools and biomarkers was highlighted.
Conclusions:
- Optimal antithrombotic therapy for CVD prevention requires personalized strategies.
- Future advancements in decision support and biomarkers are anticipated to refine treatment selection.
- Balancing the benefits and risks of antithrombotic agents is paramount for effective CVD prevention.
Abstract:
At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.